Nessuna connessione a internet — viene mostrata la versione salvata della pagina.

Sanofi ADR

USUSD
← Allo screener

Sanofi ADR (VI:SANO) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 6. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.

Informazioni sull'azienda

Sito web
sanofi.com
Settore
Health Care · Biotechnology: Pharmaceutical Preparations
Sede centrale
PARIS, France
Amministratore delegato
Paul Hudson
Dipendenti
106 566
Fondata
2004
Quotata dal
04.10.2017 (VI:SANO)
Azioni in circolazione
1.22 Mld al 2025-12-31
Flottante
2.16 Mld
Capitalizzazione di mercato
98.67 Mld USD
Insider
0%
Investitori istituzionali
8.02%
Settore (SIC)
Pharmaceutical Preparations
Forma giuridica
QVPB
ISIN
FR0000120578
LEI
549300E9PC51EN656011
Payout ratio
0%
FCF
10.8 Mld EUR
Debito
18.7 Mld EUR
1.0 anni di FCF
Serie di dividendi
23 a.
Utili, FCF e dividendi pagati — per i 12 mesi fino a 31.12.2025 (l'ultimo rapporto dell'azienda).
Descrizione

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Borse e ticker

BorsaTickerValutaPrezzoTipo
US USA StocksSNYNF OTCUSD79.9382 +2.14%azioni ordinarie
LSE London Stock Exchange0O59 IOBEUR71.63 +0.72%azioni ordinarie
MI Borsa Italiana (Milan)1SAN secondariaEUR71.64 +0.90%azioni ordinarie
PA Euronext ParisSAN principaleEUR71.52 +0.83%azioni ordinarie
VI Vienna Stock ExchangeSANO secondariaEUR71.3 +1.03%azioni ordinarie
XETRA XetraSNW secondariaEUR71.78 -1.21%azioni ordinarie

Prezzo su 3 mesi

giorno di rialzo giorno di ribasso data di stacco del dividendo data di pagamentoPassa il mouse / tocca un giorno — prezzi di apertura, chiusura, massimo e minimo

Dividendi

Ultimi 12 mesi, VI:SANO: 4.12 EUR (1 pag.)

Sanofi ADR (SANO) paga dividendi una volta all'anno. Negli ultimi 12 mesi, sono stati pagati 4.12 EUR per azione (pagamenti: 1). Questo rappresenta circa il 5.78% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 04.05.2027. Storia dei dividendi ininterrotta: 23 anni.

Data exPagamentoImporto%TipoTicker
2026-05-052026-05-074.1200 EUR5.8/5.8 %annualeVI:SANO
2025-05-122025-05-143.9200 EUR5.5/5.5 %annualeVI:SANO
2024-05-13—3.7600 EUR5.3/10.3 %annualeVI:SANO
2023-05-30—3.5600 EUR5.0/5.0 %annualeVI:SANO
2022-05-06—3.3300 EUR4.7/4.7 %annualeVI:SANO

Notizie di questa settimana

Ancora nessuna notizia dal sito della società.

pubblicità

Principali azionisti

DetentoreQuotaAzioniData del rapporto
Dodge & Cox Inc.10.54%28.09 Mln2026-06-30
Dodge & Cox Funds-Dodge…7.84%20.9 Mln2026-06-30
Morgan Stanley4.02%10.7 Mln2026-06-30
Fisher Asset Management,…3.99%10.63 Mln2026-06-30
Bank of America Corporat…3%8.01 Mln2026-06-30
Invesco Ltd.2.55%6.8 Mln2026-06-30
JPMORGAN CHASE & CO2.47%6.57 Mln2026-06-30
Mondrian Investment Part…2.07%5.52 Mln2026-06-30
Brandes Investment Partn…1.55%4.14 Mln2026-06-30
AIM Sector Funds (Invesc…1.51%4.03 Mln2026-04-30
Federated Hermes, Inc.1.44%3.85 Mln2026-06-30
Boston Partners1.44%3.84 Mln2026-06-30
VANGUARD STAR FUNDS-Vang…1.31%15.85 Mln2026-07-31
Putnam ETF Trust-Putnam…1.26%3.36 Mln2026-05-31
VANGUARD TAX-MANAGED FUN…0.87%10.53 Mln2026-06-30
iShares Trust-iShares Co…0.67%8.11 Mln2026-08-31
Dodge & Cox Funds-Dodge…0.63%1.67 Mln2026-06-30
AMERICAN MUTUAL FUND0.59%1.58 Mln2026-06-30
American Century Capital…0.37%976 5612026-06-30
Bridge Builder Trust-Bri…0.36%967 1002026-06-30
Fidelity Concord Street…0.35%4.24 Mln2026-07-31
VanEck ETF Trust-VanEck…0.35%938 5612026-08-31
Dodge & Cox Funds-Dodge…0.33%4.04 Mln2026-06-30
iShares Trust-iShares MS…0.32%3.89 Mln2026-08-31
Capital World Growth & I…0.3%3.67 Mln2026-06-30
-Victory Pioneer Core Eq…0.3%799 4872026-06-30
Fidelity Covington Trust…0.3%797 1842026-08-31
NEW PERSPECTIVE FUND0.29%3.56 Mln2026-06-30
Federated Hermes Eqy. Fd…0.29%3.48 Mln2026-07-31
Bridge Builder Trust-Bri…0.29%3.44 Mln2026-06-30
Pacer Advisors, Inc.0.1%1.16 Mln2026-06-30
Generali Investments Cee…0%29 3392026-06-30
Paradigm Asset Managemen…0%19 2002026-06-30
Gamma Investing LLC0%582026-06-30
L'Oréal———